Table 1.
Summary table of clinical trials carried out on NTG in cancer therapy.
| Stage (Patient number) | Associated treatment | Method of administeringNTG | Administration cycle | Ref. |
|---|---|---|---|---|
| Non-small cell lung cancer (NSCLC) | ||||
| Phase II | ||||
| Operable lung adenocarcinoma (17) | Surgery | NTG patch (25 mg) |  |
[87] |
| Advanced lung adenocarcinoma (29) | Docetaxel (60 mg/m²) + Carboplatin (target area under the curve (AUC) 5) | NTG patch (25 mg) |  |
[87] |
| IIIB/IV (120) | Vinorelbine (25 mg/m²) + Cisplatin (80 mg/m²) | NTG patch (25 mg) |  |
[89] |
| IIIB/IV (66) | Vinorelbine (60–80 mg/m²) + Cisplatin (80 mg/m²) | NTG patch (25 mg) |  |
[90] |
| IIIA-IIIB (35) | Vinorelbine (25 mg/m²) + Cisplatin (70 mg/m²) + radiotherapy | NTG patch (25 mg) |  |
[91] |
| IV non-squamous (223) | Carboplatin (area under the curve 6) + Paclitaxel (200 mg/m²) + Bevacizumab (15 mg/kg) | NTG patch (15 mg) |  |
[92] |
| III/IV (70) | Docetaxel (75 mg/m²) + Carboplatin | Micro-pump of NTG (20-50 µg/min) |  |
[88] |
| IB-IV (42) | Radiotherapy | NTG patch (25 mg) | Patch is applied 2 h before the radiotherapy session and removed after | [94] |
| Phase III | ||||
| IIIB/ IV (372) | Carboplatin + Gemcitabine (79%) Or Carboplatin + Paclitaxel (18%) or Cisplatin + Vinorelbine (2%) | NTG patch (25 mg) |  |
[99] |
| Prostate cancer | ||||
| Phase II | ||||
| Biochemical recurrence of prostate cancer after primary therapy (29) | Radiotherapy or surgery | NTG patch delivering 0.033 mg/h (1/6 of patch) | Patch applied continuously for 24 months | [95] |
| Liver cancer | ||||
| Phase II | ||||
| Hepatocellular Carcinoma (HCC) BCLC stage A or B (101) | Transcatheter Arterial (Chemo)Embolization (TAE/TACE) | Intravenous NTG (100 µg) | Injection of NTG via the catheter before the Lipiodol or Lipiodol/Doxorubicin emulsion | [96] |
| Rectal cancer | ||||
| Phase I | ||||
| Locoregionally advanced operable rectal cancer (13) | 5-fluorouracil (225 mg/m²) + Radiotherapy | NTG patch delivering 0.2, 0.4 or 0.6 mg/h | Patch is applied 2 h before the chemoradiotherapy session and 12 h each day of chemoradiotherapy. The 5-fluorouracil is administrated with continuous infusion throughout duration of the radiotherapy | [98] |
The arrow indicates the administration of chemotherapies or the surgery on day 1. In all clinical studies right above, the chemotherapies were injected on day 1 (as indicated by the arrow in Table 1) except for vinorelbine which is also injected on day 8. Different association of chemotherapies can be used for the treatment of NSCLC like docetaxel and carboplatin, vinorelbine and cisplatin or carboplatin and paclitaxel with bevacizumab (a monoclonal antibody directed against VEGF). The NTG patches were applied a few days before administration of the chemotherapy (3, 2 or 1 days) and then for 5 days.
B Bevacizumab, Ca Carboplatin, Ci Cisplatin, D Docetaxel, G Gemcitabine, NTG Nitroglycerin, P Paclitaxel, V Vinorelbine.